Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy

Sponsor

Xiamen Amoytop Biotech Co., Ltd. (Industry)

Overall Status

Completed

CT.gov ID

NCT04466137

Collaborator

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Other)

398

Enrollment

Location

Arms

10.5

Actual Duration (Months)

37.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This phase 3 study is aimed to evaluate the safety and efficacy of YPEG-rhG-CSF in reducing the infection manifested by febrile neutropenia in patients with non-myeloid malignancy who receiving Myelosuppressive Chemotherapy which is likely to cause clinically significant febrile neutropenia.

Condition or Disease	Intervention/Treatment	Phase
Non-Myeloid Malignancy	Drug: YPEG-rhG-CSF Drug: YPEG-rhG-CSF Drug: rhG-CSF/PEG-rhG-CSF	Phase 3

Study Design

Study Type:

Interventional

Actual Enrollment :

398 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multi-centers, Randomized, Open-labeled, Positive-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF, Once-per-cycle, in Patients With Malignancies Receiving Myelosuppressive Chemotherapy.

Actual Study Start Date :

Oct 16, 2020

Actual Primary Completion Date :

Jun 24, 2021

Actual Study Completion Date :

Sep 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: YPEG-rhG-CSF 2mg YPEG-rhG-CSF 2mg	Drug: YPEG-rhG-CSF YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
Experimental: YPEG-rhG-CSF 33μg/kg YPEG-rhG-CSF 33μg/kg	Drug: YPEG-rhG-CSF YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.
Active Comparator: Positive Control Group rhG-CSF/PEG-rhG-CSF	Drug: rhG-CSF/PEG-rhG-CSF rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.

Arm

Intervention/Treatment

Experimental: YPEG-rhG-CSF 2mg

YPEG-rhG-CSF 2mg

Drug: YPEG-rhG-CSF

YPEG-rhG-CSF 2mg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.

Experimental: YPEG-rhG-CSF 33μg/kg

YPEG-rhG-CSF 33μg/kg

Drug: YPEG-rhG-CSF

YPEG-rhG-CSF 33μg/kg, single s.c. at day 3 of each cycles, up to 4 cycles. 21 day one cycles.

Active Comparator: Positive Control Group

rhG-CSF/PEG-rhG-CSF

Drug: rhG-CSF/PEG-rhG-CSF

rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.

Outcome Measures

Primary Outcome Measures

Mean Duration of Severe Neutropenia (DSN) During Cycle 1. [At the end of Cycle 1 (21 days one cycle)]
Mean duration of severe neutropenia, defined as number of consecutive days with absolute neutrophil count (ANC) <0.5 × 10^9 cells/l (grade 4 neutropenia)

Secondary Outcome Measures

Incidence of Febrile neutropenia(FN). [Cycle1 to Cycle 4(21 days one cycle)]
FN defines as the ANC counts is less than < 0.5 × 10^9 cells/L or ANC counts between 0.5 × 10^9 cells/L and 1.0 × 10^9 cells/L but probably to decline to less than 0.5×10^9 cells/L within 48hrs, and body temperature is higher than 38.3 degrees Celsius or higher than 38.0 degrees Celsius and lasting for more than 1hr.
Mean duration of DSN. [Cycle2 to Cycle 4 (21 days one cycle)]
Incidence of Grade 3 neutropenia. [Cycle1 to Cycle 4 ( 21 days one cycle)]
Grade 3 neutropenia defines as the ANC count is less than 1.0×10^9 cells/L.
Mean duration of grade 3 neutropenia. [Cycle1 to Cycle 4(21 days one cycle)]
Neutrophils dynamic changes from baseline. [Cycle1 to Cycle 4 ( 21 days one cycle)]
Time of neutrophils recovering to over 2.0×10^9 cells/L after nadir. [Cycle1 to Cycle 4 (21 days one cycle)]
Proportion of patients with antibiotic usage. [Cycle1 to Cycle 4 ( 21 days one cycle)]
Proportion of patients experienced infection. [Cycle1 to Cycle 4 ( 21 days one cycle)]
Proportion of patients fulfilling expected chemotherapy. [Cycle1 to Cycle 4 (21 days one cycle)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histopathology and/or cytology diagnosed as breast cancer (BC) or non-small cell lung cancer (NSCLC), and patients with breast cancer is suitable to receive TAC(Docetaxel,Doxorubicin combined with Cyclophosphamide) chemotherapy, while patients with NSCLC is suitable to receive DC(Docetaxel combined with Carboplatin) chemotherapy.
Age ≥18 yrs.
Weight ≥45 kg.
Karnofsky Score ≥ 70.
Life Expectancy ≥ 3 months.
Peripheral blood test: WBC≥3.5×10^{9 cells/L, PLT≥100×10}9 cells/L. ANC≥1.5×10^9 cells/L.
Understand and voluntarily sign the informed consent form.

Exclusion Criteria:

Receiving chemotherapy within two months prior to screening.
Previously or plan to receive radiotherapy (>25% total bone marrow volume).
Evidence of tumor metastasis in bone marrow.
Lack of awareness.
Uncontrolled infection or using of antibiotics within 72hrs prior to screening.
Previously received or plan to undergoing bone marrow or organ transplants.
Patients with bleeding tendency, e.g. prolonged prothrombin time of more than 3 seconds.
Dysfunction in heart,lung, liver, kidney, or other major organs or systems; ALT>2.5 ULN (upper limit of normal), TBil >2.5 ULN (ALT>2.5 ULN, total bilirubin >2.5 ULN for patients with liver metastasis), HBsAg positive, anti-HCV positive, evidence of liver decompensation, or Cr >1.5 ULN.
Pregnant or lactating females.
Malignancy other than BC or NSCLC.
Hypersensitivity to rhG-CSF or any component of the investigational Products.
Subject enrolled in any other studies within 3 months prior to screening.
Drug abuser or alcoholics.
Any other conditions which in the opinion of the investigator precluded enrollment into the study.